Goldie-Coldman and bevacizumab beyond disease progression

    loading  Checking for direct PDF access through Ovid

Abstract

Targeted therapies offer new hope in overcoming the challenges encountered with conventional chemotherapy. However, little is known about the precise mechanisms that cause resistance. These issues are discussed in light of data from the BRiTE study, which indicate that the antiangiogenic effects of bevacizumab might persist despite the development of resistance to first-line chemotherapy.

Related Topics

    loading  Loading Related Articles